Cargando…
The Role of Osteopontin and Its Gene on Glucocorticoid Response in Myasthenia Gravis
Biomarkers that assess treatment response for patients with the autoimmune disorder, myasthenia gravis (MG), have not been evaluated to a significant extent. We hypothesized the pro-inflammatory cytokine, osteopontin (OPN), may be associated with variability of response to glucocorticoids (GCs) in p...
Autores principales: | Xie, Yanchen, Li, Hai-Feng, Sun, Liang, Kusner, Linda L., Wang, Shuhui, Meng, Yunxiao, Zhang, Xu, Hong, Yu, Gao, Xiang, Li, Yao, Kaminski, Henry J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5450020/ https://www.ncbi.nlm.nih.gov/pubmed/28620344 http://dx.doi.org/10.3389/fneur.2017.00230 |
Ejemplares similares
-
Serum metabolomics of treatment response in myasthenia gravis
por: Sikorski, Patricia, et al.
Publicado: (2023) -
Serum Metabolomic Response of Myasthenia Gravis Patients to Chronic Prednisone Treatment
por: Sengupta, Manjistha, et al.
Publicado: (2014) -
TNFAIP3 gene rs7749323 polymorphism is associated with late onset myasthenia gravis
por: Yang, Hong-Wei, et al.
Publicado: (2017) -
Editorial: Advances in Autoimmune Myasthenia Gravis
por: Punga, Anna Rostedt, et al.
Publicado: (2020) -
Differential RNA Expression Profile of Skeletal Muscle Induced by Experimental Autoimmune Myasthenia Gravis in Rats
por: Kaminski, Henry J., et al.
Publicado: (2016)